pre-seed
Stage
1
Investors
About
KiraGen develops off-the-shelf multiplex gene-edited CAR-T cell therapies designed to resist tumor suppression signals and function robustly within suppressive tumor microenvironments, with an initial focus on glioblastoma multiforme (GBM).
Explore KiraGen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.